CONMED Co. (NASDAQ:CNMD) CFO Luke A. Pomilio sold 1,962 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $60.25, for a total transaction of $118,210.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Luke A. Pomilio also recently made the following trade(s):
- On Thursday, February 1st, Luke A. Pomilio sold 18,023 shares of CONMED stock. The shares were sold at an average price of $63.38, for a total transaction of $1,142,297.74.
CONMED Co. (CNMD) traded down $0.27 on Tuesday, hitting $61.00. 171,597 shares of the stock traded hands, compared to its average volume of 196,971. CONMED Co. has a 1 year low of $39.74 and a 1 year high of $64.99. The stock has a market capitalization of $1,710.00, a PE ratio of 73.82, a price-to-earnings-growth ratio of 2.49 and a beta of 0.74. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.56 and a quick ratio of 1.49.
CONMED (NASDAQ:CNMD) last announced its earnings results on Wednesday, January 31st. The medical technology company reported $0.69 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.04. CONMED had a net margin of 6.97% and a return on equity of 9.15%. The business had revenue of $222.60 million during the quarter, compared to analysts’ expectations of $212.17 million. During the same period in the prior year, the company earned $0.54 earnings per share. The firm’s revenue was up 9.1% on a year-over-year basis. equities analysts predict that CONMED Co. will post 2.14 earnings per share for the current year.
Hedge funds have recently made changes to their positions in the business. Piedmont Investment Advisors LLC purchased a new stake in CONMED during the second quarter valued at approximately $273,000. Macquarie Group Ltd. increased its holdings in CONMED by 13.9% during the third quarter. Macquarie Group Ltd. now owns 731,957 shares of the medical technology company’s stock valued at $38,406,000 after buying an additional 89,078 shares during the last quarter. Prudential Financial Inc. increased its holdings in CONMED by 65.8% during the third quarter. Prudential Financial Inc. now owns 118,365 shares of the medical technology company’s stock valued at $6,211,000 after buying an additional 46,956 shares during the last quarter. Rothschild Asset Management Inc. increased its holdings in CONMED by 52.5% during the third quarter. Rothschild Asset Management Inc. now owns 53,721 shares of the medical technology company’s stock valued at $2,819,000 after buying an additional 18,489 shares during the last quarter. Finally, Epoch Investment Partners Inc. increased its holdings in CONMED by 2.1% during the third quarter. Epoch Investment Partners Inc. now owns 232,576 shares of the medical technology company’s stock valued at $12,203,000 after buying an additional 4,839 shares during the last quarter. 98.57% of the stock is owned by institutional investors and hedge funds.
CNMD has been the subject of several research reports. Zacks Investment Research raised shares of CONMED from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. KeyCorp reissued a “hold” rating on shares of CONMED in a report on Friday, November 3rd. Piper Jaffray Companies reissued a “hold” rating and set a $46.00 price objective on shares of CONMED in a report on Friday, November 3rd. Finally, BidaskClub cut shares of CONMED from a “hold” rating to a “sell” rating in a report on Tuesday, December 12th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $59.00.
WARNING: This piece of content was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2018/02/20/insider-selling-conmed-co-cnmd-cfo-sells-1962-shares-of-stock-updated.html.
CONMED Company Profile
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.